Associated Regional and University Pathologists Laboratories, 500 Chipeta Way, Salt Lake City, UT 84108, USA.
J Mol Diagn. 2010 Mar;12(2):244-9. doi: 10.2353/jmoldx.2010.090091. Epub 2010 Jan 28.
Chronic lymphocytic leukemia (CLL) is the most common leukemia affecting adults in the western world. The clinical course of CLL is highly variable: cases that express mutated immunoglobulin heavy chain variable regions (IgV(H)) typically have a more indolent clinical course compared with those with unmutated IgV(H). The use of the V(H)3-21 variable region has also been found to confer a poor prognosis, independent of mutation status. Here we describe an assay for the identification of the expressed V(H) segment and its mutation status in CLL. This test uses whole blood-derived RNA and PCR primers annealing to the leader regions and the joining region segments. This approach allows more accurate determination of the IgV(H) mutation status relative to using framework region specific V(H) primers. An additional primer specific for the leader region of the V(H)3-21 segment is described and is shown to be necessary to identify this diagnostically important variable region. We successfully analyzed 99 of 103 samples, including five expressing the V(H)3-21 variable region. Approximately 5% of cases had complement determining region 3 sequences similar to previously reported cases, and overrepresentation of the V(H)1-69 segment was observed among unmutated cases. These results confirm the proper functioning and high success rate of this valuable prognostic for CLL designed for the use in a clinical laboratory setting.
慢性淋巴细胞白血病(CLL)是西方世界成人中最常见的白血病。CLL 的临床病程高度可变:表达突变免疫球蛋白重链可变区(IgV(H))的病例通常比未突变 IgV(H)的病例具有更惰性的临床病程。已经发现 V(H)3-21 可变区的使用也与突变状态无关,预后不良。在这里,我们描述了一种用于鉴定 CLL 中表达的 V(H) 片段及其突变状态的检测方法。该测试使用全血衍生的 RNA 和退火到先导区和连接区片段的 PCR 引物。与使用框架区特异性 V(H) 引物相比,这种方法可以更准确地确定 IgV(H) 的突变状态。描述了一个针对 V(H)3-21 片段的先导区的特异性引物,并且证明该引物对于鉴定这个具有诊断意义的重要可变区是必要的。我们成功地分析了 103 个样本中的 99 个,包括 5 个表达 V(H)3-21 可变区的样本。大约 5%的病例的补体决定区 3 序列与先前报道的病例相似,并且在未突变的病例中观察到 V(H)1-69 片段的过度表达。这些结果证实了这种针对 CLL 的有价值的预后检测方法在临床实验室环境中的正确功能和高成功率,该方法是为临床实验室环境设计的。